{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"The 6-month progression-free rate is defined as the total number of efficacy-evaluable patients on study without documentation of disease progression 6 months from registration divided by the total number of efficacy-evaluable patients enrolled on study.","groups":[{"description":"Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\ntemsirolimus: Given IV","id":"OG000","title":"Treatment (Temsirolimus)"}],"populationDescription":"The study concluded terminated early and patients were not followed.","reportingStatus":"POSTED","timeFrame":"6 months from registration","title":"Progression Free Survival","type":"PRIMARY"}